The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217547 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Xiao-Hang Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: MDS1 and EVI1 Complex Locus Protein, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Key Research and Development Program of China, Beijing Municipal Science and Technology Commission.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) with 3q26 rearrangements results in a poor prognosis and typically causes ecotropic viral integration site1 (EVI1) overexpression (EVI1oe); however, many AML patients with EVI1oe have undetected 3q26 rearrangements. The aim of this study was to restratify AML patients with EVI1oe. We retrospectively reviewed the diagnostic outcomes of 1327 patients tested at our institute from November 2015 to December 2022. A total of 468 de novo AML patients were included, with 191 classified as EVI1oe. Eighteen AML patients with EVI1oe had detectable 3q26 rearrangements and had significantly greater EVI1 expression levels than those without rearrangements. A new cutoff value for EVI1oe in AML patients of 122 % was determined using the ROC curve based on overall survival (OS) and effectively distinguished the prognosis of EVI1oe AML patients without detectable 3q26 rearrangements (p = 0.0051 and 0.0039, respectively). Using this cutoff value, ELN stratification, transplantation status, response to induction therapy, and bone marrow blast percentage, we constructed a nomogram model (C-index = 0.808). This model was used to stratify patients into two risk subgroups, with the low-risk subgroup showing better OS than the high-risk subgroup did (p < 0.001 in the training cohort; p = 0.002 in the validation cohort). In conclusion, AML patients with EVI1oe have heterogeneous prognoses. The use of EVI1 expression levels in combination with other risk factors may enable accurate prognostic stratification of AML patients with EVI1oe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
Förderung
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
- National Key Research and Development Program of China
- Beijing Municipal Science and Technology Commission
Zitieren
APA
Ma, X. H., Gao, M. G., Cheng, R. Q., Qin, Y. Z., Duan, W. B., Jiang, H., Huang, X. J., & Zhao, X. S. (2025). The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217547
Vancouver
Ma XH, Gao MG, Cheng RQ, Qin YZ, Duan WB, Jiang H, et al. The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217547
BibTeX
@article{Ma2025,
author = {Ma, Xiao-Hang and Gao, Meng-Ge and Cheng, Rong-Qi and Qin, Ya-Zhen and Duan, Wen-Bing and Jiang, Hao and Huang, Xiao-Jun and Zhao, Xiao-Su},
title = {The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217547}
}
EUVIMED